Knowledge of the impact of different conditioning regimens used in bone marrow transplantation on spermatogenesis is important in pre-BMT counselling for three reasons: (1) Most young patients who have not had children are concerned with their subsequent fertility; (2) For a number of diseases there are competing therapeutic options that may affect spermatogenesis more or less seriously; (3) Since spontaneous recovery of spermatogenesis is rare, it would be necessary to offer cryopreservation as soon as possible after diagnosis and prior to any treatment. This retrospective study evaluates 99 semen samples obtained in 64 patients who underwent BMT between 1982 and 1996. Recovery of spermatogenesis was observed in 90% of patients conditioned with cyclophosphamide (CY), in 50% of patients with CY plus busulphan (BU) or thiotepa and in 17% of patients with CY plus total body irradiation (TBI) or thoracoabdominal irradiation (TAI). Sperm quality following CY was within the normal range (WHO) in the majority of patients, whereas it was consistently severely impaired in patients who received irradiation or two alkylating agents. Following CY, spermatogenesis recovery was observed in 60% of patients tested 1 year post transplant and it was accomplished within the third year in 80% of cases. Keywords: bone marrow conditioning; spermatogenesis recovery; fertility counselling Due to improved survival following BMT for aplastic anemia or lymphohematological malignancies, there is a growing issue about counselling regarding subsequent fertility status. In addition, the introduction of new conditioning regimens could have a different impact on male reproduction. Although semen cryopreservation should always be suggested before starting any cytotoxic treatment, very often this procedure cannot be performed for various reasons. Firstly, when facing the diagnosis of cancer at a young age, patients and often their physicians, may not be prepared to plan for future fertility difficulties before starting therapy. Secondly, freezing may not readily be available in all oncological centers. Thirdly, in some patients poor sperm quality, due to the cancerous state itself, was previously considered to render semen unsuitable for freezing until the introduction of intracytoplasmic sperm injection (ICSI), a new technique which permits in vitro fertilization with few spermatozoa. The aim of the present study was to evaluate the degree, quality and kinetics of spermatogenesis recovery in 64 patients receiving various myeloablative regimens.
Due to improved survival following BMT for aplastic anemia or lymphohematological malignancies, there is a growing issue about counselling regarding subsequent fertility status. In addition, the introduction of new conditioning regimens could have a different impact on male reproduction. Although semen cryopreservation should always be suggested before starting any cytotoxic treatment, very often this procedure cannot be performed for various reasons. Firstly, when facing the diagnosis of cancer at a young age, patients and often their physicians, may not be prepared to plan for future fertility difficulties before starting therapy. Secondly, freezing may not readily be available in all oncological centers. Thirdly, in some patients poor sperm quality, due to the cancerous state itself, was previously considered to render semen unsuitable for freezing until the introduction of intracytoplasmic sperm injection (ICSI), a new technique which permits in vitro fertilization with few spermatozoa. The aim of the present study was to evaluate the degree, quality and kinetics of spermatogenesis recovery in 64 patients receiving various myeloablative regimens.
Patients and methods
In December 2000, the clinical charts of 64 males who underwent allogeneic BMT between 1982 and 1996, in the Department of Hematology, San Martino Hospital, Genoa, Italy who had had at least one semen analysis after treatment, were reviewed.
Type of malignancy, previous chemotherapy treatment, conditioning regimen, age at BMT and previous reproductive history were obtained for each patient, as well as the fertility follow-up. Most semen analyses were performed in the Andrology Laboratory of the Department of Obstetrics and Gynaecology at the University of Genoa. Semen specimens were collected by masturbation after 3 days of sexual abstinence. Semen analysis consisted of an evaluation of volume, sperm motility and sperm count by standard methods according to subsequent WHO proto-Bone Marrow Transplantation   13  12  11  10  9  8  7  6  5  4  3  2  1  0  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 cols. 1 Patients were considered to be azoospermic when no spermatozoa were detected in the sample in any fields of a double-chambered hemacytometer (Neubauer Improved) before and after centrifugation. When spermatozoa were detected only after centrifugation, patients were considered to be cryptospermic. Severe oligozoospermia was defined when the sperm count was <5 ϫ 10 6 /ml, oligozoospermia when the sperm count was between 5 and 20 ϫ 10 6 /ml and normozoospermia when the sperm count was >20 ϫ 10 6 /ml. Sperm motility was assessed with a simple grading system according to the WHO protocol.
1 Sperm morphology was assessed on stained preparations (Papanicolaou's staining) using a 100ϫ oil immersion bright-field objective and a 10ϫ eye piece (Leitz), when at least 200 spermatozoa were available for examination.
All data collected were evaluated with a computerized system and analyzed with SAS (release V8, SAS Institute, Cary, NC, USA). Chi-square or Fisher exact tests were used for categories and a general linear model (GLM) for quantitative variables. Correlation analysis was also applied to evaluate the reciprocal distribution of variables.
Results
The mean age of patients at transplant was 27.39 Ϯ 8.16 (9-50 ). Eighteen patients (28%) had had one or more children before undergoing BMT. Only eight had had a semen analysis before BMT and among them 75% showed normozoospermic parameters. Indications for BMT were as follows: severe aplastic anaemia (SAA, n ϭ 11), acute lymphocytic leukaemia (ALL, n ϭ 7), acute myelogenous leukaemia (AML, n ϭ 25), chronic myelocytic leukaemia (CML, n ϭ 17), nonHodgkin's lymphoma (NHL, n ϭ 3) and one case of Hodgkin's disease (HD).
The transplant preparative regimen and results of the last semen sample performed after BMT are reported in Table  1 . Follow-up ranges from 1 to 18 years (median 4 years).
Before referral for BMT all patients with malignancies had received various doses and schedules of chemotherapy. In 45 cases it was possible to estimate the time elapsed from the end of chemotherapy and BMT, which ranged between 1 day and 31 months (mean 158.7 days) and was 100 or more days in 60% of cases (27 out of 45 patients).
Incidence of azoospermia after BMT
The highest incidence of azoospermia following BMT was found in patients prepared with CY plus TBI or TAI (85.4%). Among patients conditioned with CY plus BU or thiotepa 50% remained azoospermic. Conversely, 10% of patients who received only CY showed azoospermia. The only patient prepared with CY who did not show recovery of spermatogenesis had had the last semen sample only 2 years after BMT.
No statistical correlation between age at BMT and recovery of spermatogenesis was demonstrated.
Quality of spermatogenesis recovery
Among patients who recovered some degree of spermatogenesis (Table 2) , normozoospermia, as defined by WHO criteria, was observed in eight patients after conditioning with CY and in one patient (CVi) after conditioning with CY plus TBI.
Kinetics of spermatogenesis recovery
Twenty-two patients had more than one semen analysis at various times following BMT. Kinetics of recovery of spermatogenesis could not be statistically analyzed due to the irregular distribution of observations over the various time intervals (Figures 1 and 2) . Following CY + TBI, spermatogenesis recovery was not observed before the 4th year post transplant and in two cases it was demonstrated, respectively, after 6 and 8 years according to azoospermic samples. Following the CY conditioning regimen spermatogenesis recovery was observed in 60% of patients tested 1 year post transplant.
Paternity after BMT
Six patients' partners conceived spontaneously following BMT (Table 2) . Neither genetic defects nor malformations were recorded among the seven babies born. 
Discussion
Although pregnancies have been reported following BMT, in most cases paternity was not verified and conception, especially with TBI conditioning regimens, may be regarded as a sporadic event. [2] [3] [4] [5] [6] Moreover, even though the incidence of congenital anomalies recorded in live-born infants spontaneously conceived after treatment for lymphohematologic malignancies are comparable with that reported in the general population, 2 possible long-term gen-
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etic damage on spermatozoa cannot be excluded. Many animal studies have investigated the possible adverse effect of radiation and chemotherapy on the offspring of treated males. 7, 8 In humans, a transient increase in sperm aneuploidy within 100 days after chemotherapy [9] [10] [11] has been documented.
Based on these arguments, semen banking should be offered to all male patients undergoing BMT, before any treatment, even when spermatogenesis is already impaired as a consequence of the lymphohematological malignancy.
Intracytoplasmic sperm injection (ICSI) has, in fact, increased the chances of treating men with poor sperm counts and any sample where even an occasional spermatozoa can be detected is now considered suitable for banking. 12, 13 Another issue that requires addressing in the present discussion is whether or not sperm banking might also be proposed to patients who have already started chemotherapy, if it has not been done earlier. To address this issue, we analyzed semen samples taken before BMT from 30 patients with the same characteristics and diseases as the study population who had undergone various chemotherapy schemes. The large majority of these patients would have had the minimum criteria for semen cryopreservation, only five (16.6%) being azoospermic.
Although feasible in the majority of patients, sperm banking at this stage could be (1) denied in any case on the basis of animal data reporting genetic damage in offspring; (2) allowed only if 100 or more days have elapsed (60% of cases in this study) from the end of chemotherapy, on the basis of data on the high incidence of aneuploidy reported in human spermatozoa; (3) allowed at any time, after informing the patient prior to cryopreservation that he might not be able to use the sample if new data on negative long-term genetic effects of chemotherapy on sperm were to become available.
The negative impact of the most commonly used conditioning regimen (CY + TBI) for allogeneic BMT on sperm count was demonstrated about 20 years ago.
14 Sanders et al 14 evaluated gonadic function 1-11 years after BMT and reported spermatogenesis in 10 of 15 men prepared with CY and in only two of 32 men prepared with CY plus TBI. Since the Sanders paper, no larger study reporting data on spermatogenesis following BMT has been published. Jacob et al 15 reported 42 patients who underwent allogeneic or autologous BMT or peripheral stem cell transplant, although they obtained semen samples from only 25 patients. A recent publication evaluating the effect of the busulfan-cyclophosphamide conditioning regimen for BMT reported detectable sperm in 21 of the 26 men studied, a median of 5 years post transplant. 16 The present study, reporting results of 99 semen samples obtained following BMT in 64 patients, provides additional information supporting patient counselling and the need for planning more precise timing of follow-up semen analysis in these patients.
The incidence of azoospermia after TBI may be overestimated due to the length of follow-up. In the present study, recovery of spermatogenesis was demonstrated as late as the 9th year post transplant in a patient who was azoospermic 1 year earlier. On the other hand, 22 patients (45.8%) were classified azoospermic on the basis of a semen sample obtained at or before the 4th year post transplant. The number of cases conditioned with CY-BU or CY-thio is not large enough to draw conclusions. The trend toward a higher spermatogenesis recovery rate recorded after these regimens in comparison with CY-TBI (P ϭ 0.069), if confirmed in larger studies, would favor the choice of BU or thiotepa for conditioning young male patients. With the CY conditioning regimen spermatogenesis is maintained in a larger number of cases (90%).
It has previously been shown that gonadal recovery in women is dependent on age and menarchal status at the time of BMT. 17 In this study, male age at transplant did not show a correlation with spermatogenesis recovery.
We can not draw definitive conclusions on the kinetics of spermatogenesis recovery following BMT due to the retrospective nature of the study, which did not allow recording of all samples required for statistical analysis. Nevertheless, on the basis of our experience, we suggest patients undergoing CY conditioning be tested from 1 year post transplant onwards, whereas following TBI, patients should not be tested before the 4th year post BMT. Moreover, following TBI, it is important to continue follow-up for a longer period of time (even 9-10 years) before drawing conclusions on a patient's fertility status.
